Clinical-stage precision immunotherapy developer using immunopeptidomics and protein engineering to target tumor-specific intracellular peptides in solid cancers. Lead precision-engineered CAR-T therapy for neuroblastoma in Phase 1b; platform compatible with multiple immunotherapies and designed for broad HLA allotype coverage.